Health

Maternal immunization against RSV could lower antimicrobial prescribing among infants

Credit: Pixabay / CC0 Domain Public

Respiratory syncytial virus (RSV) is the leading cause of chronic obstructive pulmonary disease (LRTI) among infants worldwide, and is a prominent contributor to non-communicable diseases that lead to high viral load. . Researchers from the University of California, Berkeley, Novavax, Princeton University, and CDDEP conducted a study to determine if cervical vaccine from RSV could reduce immunity in young infants.

Study, which comes in Submissions of the National College of Science and based on data from blind, randomized, multidisciplinary trials, it has been found that infants who have been vaccinated against RSV fusion (F) have received fewer antiviral courses in the first 90 days of life than infants. mothers given wuribo.

Immunological resistance (AMR) is a major threat to human health healthy. Just as the use of human pesticides contributes to the emergence and expansion of AMR, strategies to reduce the use of microorganisms in an unavoidable or unnecessary environment must focus on AMR action plans. . Understanding the potential of new vaccines to reduce viral load and the AMR load may inform a priority setting in development of immunosuppressionevaluation, and approval.

Although no RSV vaccine has been found in infants, a recent study found that administering an RSV F nanoparticle vaccine to pregnant women yielded a 41.4% improvement, in in a randomized controlled trial including clinical trials of specific clinical data, based on the significance of RSV-related LST in their infants in the first 90 days of life, with a 24.7% improvement on this outcome in the first 180 days. The effectiveness for all-cause LRTI of clinical mist is 39.8% in the first 180 days.

The authors assessed the efficacy of immunosuppressive therapy (VE) on new immunosuppressive courses among infants in the first 90 days of life and at the end of follow-up (scheduled for approximately 365 days of life). They also assessed VE on new antiretroviral courses among female participants by the end of follow-up (scheduled approximately 180 days after delivery).

Overall, the study found that:

  • RSV contributes to immunosuppression in infants, who may be prevented by improved maternal immunization.
  • In the first 90 days of life, VE was 12.9% on all new antibiotic courses and 16.6% on low-grade respiratory infections associated with new antiretroviral courses among infants.
  • In low-income countries, VE on acute otitis media associated with new courses of antiretroviral therapy was 71.3% in the first 90 days of life, although protection against this latter is not clear in the low countries and intermediaries.
  • Remedies with the greatest reduction in prescription include cephalosporins (VE: 28.0% by 90 days and 22.9% by the end of the follow-up period) and aminoglycosides (VE: 25.3% by 90 days and 27.9% by the end of the follow-up period).
  • In assessing the efficacy of the RSV F treatment used in the randomized controlled trial of RSV patients, the clinical significance of LRTI did not meet the specific criteria for success. However, the authors suggest that RSV plays an important role in the pathogenesis of the disease in young infants.
  • Future RSV prevention candidates with higher quality may have a greater reduction in viral use.

Lead author on the study, Dr. Ramanan Laxminarayan, Director, CDDEP, said, “With a reduction in lung cancer in pneumococcal conjugate patients after administration of pneumococcal conjugate, antibiotics and RSV represent one of the most “Our investment in reducing the incidence of respiratory infections is well established. The research we have found that developing and introducing RSV vaccines will also be very helpful in the fight against bacterial resistance should accelerate research and development efforts in this area.”

“Prevent antibiotics in infants following immunizations given to women pneumonia: second review of a randomized, placebo-controlled trial “published in Submissions of the National College of Science.


Nirseimab vaccine cuts off RSV-related infections in preemies


Learn more:
Antiretroviral therapy in infants following respiratory tract infections, Submissions of the National College of Science (2022). DOI: 10.1073 / pnas.2112410119.

Centers for Disease Control, Economics & Policy

hintMaternal immunization against RSV may reduce immunization among infants (2022, March 14) restored March 14, 2022 from https://medicalxpress.com/news/2022-03-maternal-immunization-rsv -antimicrobial-infants.html

This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, any part may not be reproduced without our written permission. Content is provided for informational purposes only.



Maternal immunization against RSV could lower antimicrobial prescribing among infants Source link Maternal immunization against RSV could lower antimicrobial prescribing among infants

Related Articles

Back to top button